MedTrace Logo

adaptatiVe Endovascular Strategy to the CloT MRI in Large Intracranial Vessel Occlusion

NCT04139486 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 526

Last updated 2022-12-16

No results posted yet for this study

Summary

In the VECTOR trial, the aim is to analyze, in case of SVS+ occlusions, a first line Embotrap II added to CA combined strategy compare to CA alone strategy.

Many practitioners are convinced that a first line strategy with CA alone is easy, safe, rapid and efficient. Maybe, after two, three, four ... passes and with the secondary help of a combined strategy, a high rate of eTICI 2b/3 could be reached with a CA first line strategy. But this could go with a higher number of passes, a waste of time and a suboptimal angiographic results (eTICI 2b) due to distal emboli, especially in case of friable, non-well organized, red blood cell rich (RBC) i.e. SVS + thrombi (25-28). This could, be related to worst clinical outcome at 3 months. VECTOR asks a relevant question: Do the invetigators have to add the use of an Embotrap II or III to the CA, from the first passes, in case of SVS+ clots?

Conditions

  • Intracranial Thrombosis

Interventions

PROCEDURE

combined EMBOTRAP II or III and Contact Aspiration

refer to title

PROCEDURE

Contact Aspiration alone

refer to title

Sponsors & Collaborators

  • University Hospital, Lille

    collaborator OTHER

  • Central Hospital, Nancy, France

    collaborator OTHER

  • Nantes University Hospital

    lead OTHER

Principal Investigators

  • Romain Bourcier · Nantes University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-26
Primary Completion
2022-02-14
Completion
2022-10-03

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04139486 on ClinicalTrials.gov